Connor, Clark & Lunn Investment Management (CC&L)’s Krystal Biotech KRYS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,582
| Closed | -$466K | – | 1602 |
|
|
2025
Q1 | $466K | Buy |
+2,582
| New | +$466K | ﹤0.01% | 1160 |
|
|
2024
Q2 | – | Sell |
-2,296
| Closed | -$409K | – | 1536 |
|
|
2024
Q1 | $409K | Buy |
+2,296
| New | +$409K | ﹤0.01% | 1184 |
|
|
2023
Q3 | – | Sell |
-7,056
| Closed | -$828K | – | 1454 |
|
|
2023
Q2 | $828K | Buy |
7,056
+66
| +0.9% | +$7.75K | ﹤0.01% | 854 |
|
|
2023
Q1 | $560K | Sell |
6,990
-9,601
| -58% | -$769K | ﹤0.01% | 854 |
|
|
2022
Q4 | $1.31M | Sell |
16,591
-7,889
| -32% | -$625K | 0.01% | 641 |
|
|
2022
Q3 | $1.71M | Buy |
24,480
+21,278
| +665% | +$1.48M | 0.01% | 528 |
|
|
2022
Q2 | $210K | Buy |
+3,202
| New | +$210K | ﹤0.01% | 927 |
|
|
2022
Q1 | – | Sell |
-11,371
| Closed | -$795K | – | 1128 |
|
|
2021
Q4 | $795K | Buy |
+11,371
| New | +$795K | ﹤0.01% | 716 |
|